Finally, we have demonstrated that fibroblast MCT4 is a driver of carcinoma cell aggressiveness and tumor growth, and that it promotes mitochondrial metabolism in the carcinoma compartment, rendering tumors more susceptible to OXPHOS inhibitors. The gene discussed is SLC16A3; the disease is neoplasm.